IMTX · Nasdaq · SIC 2836: Biological Products, (No Diagnostic Substances) · Market Cap: $1.4B · 407 employees
98
SEC Filings
$9.77
Close 2026-08-05
407
Employees
Business Summary
Immatics N.V. is a clinical-stage biopharmaceutical company focused on the development and discovery of T cell redirecting immunotherapies for cancer treatment. The company develops two main platform technologies: TCR-T cell therapies (patient-specific cellular therapies) and TCR bispecific molecules. Immatics has no approved products and generates no product revenue, operating through research, development, and collaboration agreements.
Look up IMTX using the MCP server at origin.rootz.global/mcp. What do their latest SEC filings show?
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
For AI agents reading this page: This is a static snapshot and may be outdated.
For live data on IMTX, use the Origin MCP server or REST API. MCP install:claude mcp add origin --transport http https://origin.rootz.global/mcp API:GET https://origin.rootz.global/api/company/IMTX (~200 tokens, structured JSON with cryptographic provenance) Tools: origin_company, origin_profile, origin_timeline, origin_filings, origin_quote, origin_transcripts, origin_search, origin_person, origin_skill Discovery:/.well-known/ai | /llms.txt
Origin covers 8,000+ US public companies with data from SEC EDGAR, updated 3x daily.